Management of the contralateral testis in patients with testicular germ cell cancer

Br J Urol. 1990 Mar;65(3):290-3. doi: 10.1111/j.1464-410x.1990.tb14731.x.

Abstract

Patients with testicular germ cell tumours (TGCT) are at increased risk of developing a tumour in the contralateral testis. Such a tumour may be preceded by carcinoma in situ (CIS), which is more common in patients with infertility, atrophic testis or a history of cryptorchism. Of 1219 patients with TGCT seen at the Royal Marsden Hospital between 1962 and 1984 in whom the contralateral testis was managed by surveillance, 38 (3.1%) developed a second tumour and 8 died of germ cell tumours. Seventeen of 26 assessable patients (65%) exhibited at least one of the known aetiological risk factors for carcinoma in situ. Diagnosis of carcinoma in situ may lead to more appropriate management of the contralateral testis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma in Situ / pathology
  • Humans
  • Male
  • Neoplasms, Multiple Primary / diagnosis*
  • Neoplasms, Multiple Primary / pathology
  • Orchiectomy
  • Risk Factors
  • Teratoma / diagnosis*
  • Teratoma / pathology
  • Teratoma / surgery
  • Testicular Neoplasms / diagnosis*
  • Testicular Neoplasms / pathology
  • Testicular Neoplasms / surgery
  • Testis / pathology
  • Testosterone / therapeutic use

Substances

  • Testosterone